The French regulatory agency ANSM is streamlining its “temporary use authorization” (ATU) system to speed up individual patients’ access to new drugs that are not yet approved in France and where the patient cannot obtain the medicine through a clinical trial.
The ATU system gives patients access to unapproved new medicines where there is a pressing need, there are no therapeutic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?